Re-challenge of Anti-EGFR for Patients With RAS/BRAF Wild-type Metastatic CRC
Status:
Not yet recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
The aim of the trial is to study the efficacy and safety of Cetuximab re-challenge for
Chinese Patients with RAS/BRAF wild-type Metastatic Colorectal Cancer.